News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Innovative drug delivery and formulation
| ||||||||||||||||
| < Prev 1 2 Next > | ||||||||||||||||
| Results 1 - 9 of 10 | ||||||||||||||||



